Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Carole Ho sold 12,255 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the transaction, the insider now directly owns 178,580 shares of the company's stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock traded up $0.07 on Wednesday, hitting $21.25. The company had a trading volume of 1,245,656 shares, compared to its average volume of 1,173,671. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33. The stock has a 50 day moving average of $24.34 and a 200-day moving average of $24.88.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the firm earned ($0.72) earnings per share. Equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DNLI. Rhumbline Advisers grew its stake in Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company's stock valued at $4,525,000 after purchasing an additional 22,900 shares during the period. TD Asset Management Inc increased its holdings in Denali Therapeutics by 4.5% during the second quarter. TD Asset Management Inc now owns 179,152 shares of the company's stock worth $4,160,000 after buying an additional 7,766 shares during the last quarter. Arizona State Retirement System raised its position in Denali Therapeutics by 9.0% in the second quarter. Arizona State Retirement System now owns 33,114 shares of the company's stock worth $769,000 after acquiring an additional 2,730 shares during the period. American Century Companies Inc. boosted its stake in Denali Therapeutics by 13.7% in the second quarter. American Century Companies Inc. now owns 522,594 shares of the company's stock valued at $12,135,000 after acquiring an additional 63,058 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock valued at $32,913,000 after acquiring an additional 84,522 shares during the period. 92.92% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on DNLI. Robert W. Baird assumed coverage on Denali Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $31.00 target price on the stock. Raymond James reissued a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group upped their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Baird R W raised Denali Therapeutics to a "strong-buy" rating in a research report on Tuesday. Finally, HC Wainwright dropped their price objective on Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating on the stock in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $38.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.